Xavier Leleu

Active 2001–2026

218
Papers
35,836
Citations
94
h-index
204
i10-index

Citations

Citations per year for Xavier Leleu1988: 3 citations1990: 1 citations1993: 1 citations1999: 2 citations2001: 2 citations2002: 10 citations2003: 26 citations2004: 21 citations2005: 27 citations2006: 33 citations2007: 51 citations2008: 97 citations2009: 83 citations2010: 117 citations2011: 118 citations2012: 137 citations2013: 187 citations2014: 201 citations2015: 224 citations2016: 207 citations2017: 263 citations2018: 266 citations2019: 1,020 citations2020: 1,377 citations2021: 1,518 citations2022: 1,254 citations2023: 911 citations2024: 1,642 citations2025: 776 citations2026: 21 citations1989: no citations, so this year is not shown1991–1992: no citations, so these years are not shown1994–1998: no citations, so these years are not shown2000: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,891 citing papers, 24.3% of this breakdownChina: 896 citing papers, 7.6% of this breakdownItaly: 792 citing papers, 6.7% of this breakdownFrance: 712 citing papers, 6% of this breakdownGermany: 693 citing papers, 5.8% of this breakdownUnited Kingdom: 644 citing papers, 5.4% of this breakdownSpain: 608 citing papers, 5.1% of this breakdownNetherlands: 405 citing papers, 3.4% of this breakdownCanada: 393 citing papers, 3.3% of this breakdownGreece: 355 citing papers, 3% of this breakdownAustralia: 302 citing papers, 2.6% of this breakdownBelgium: 265 citing papers, 2.2% of this breakdown
0%24.3%Other 24.6%

Fields

  • Medicine74.5%
  • Biochemistry, Genetics and Molecular Biology19.9%
  • Immunology and Microbiology3.9%
  • Engineering0.3%
  • Computer Science0.3%
  • Pharmacology, Toxicology and Pharmaceutics0.2%
  • Other0.9%

Topics

  • Multiple Myeloma Research and Treatments19.6%
  • Protein Degradation and Inhibitors8.8%
  • Peptidase Inhibition and Analysis4.7%
  • CAR-T cell therapy research3.9%
  • Chronic Lymphocytic Leukemia Research2.9%
  • Ubiquitin and proteasome pathways2.7%
  • Other57.4%

Coauthors

All papers

Open in search
  1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert A. Kyle, Kenneth C. Anderson, Brian G.M. Durie, Jesús F. San Miguel - The Lancet Oncology 2014 cited by 4,869

  2. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carolyn C. Jackson, Kaitlyn Connors, Katherine Li, Enrique Zudaire, Diana Chen, Jane Gilbert, Tzu‐Min Yeh, Sarah Nagle, Erika Florendo, Lida Pacaud, Nitin Patel, Simon J. Harrison, Hermann Einsele - New England Journal of Medicine 2023 cited by 733

  3. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Véronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez‐Otero, Joan Bladé, Philippe Moreau - New England Journal of Medicine 2023 cited by 515

  4. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Soraya Wuillème, Sonja Zweegman, Brigitte Kolb, Cyrille Touzeau, Murielle Roussel, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Jean Paul Fermand, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Sen Hong Zhuang, Christopher Chiu, Lixia Pei, Carla de Boer, Elena Smith, William Deraedt, Tobias Kampfenkel, Jordan M. Schecter, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld - The Lancet 2019 cited by 953

  5. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 1,234

  6. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 987

  7. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kim Kihyun, Gracia Martınez, Min Chang‐Ki, Luděk Pour, Xavier Leleu, Albert Oriol, Koh Youngil, Kenshi Suzuki, Tom Martin, Hang Quach, Andrew Lim, Helen Crowther, Hanlon Sia, Cyrille Hulin, Mohamad Mohty, Gábor Mikala, Zsolt Nagy, Marta Reinoso Segura, Laura Rosiñol, Münci Yağcı, Mehmet Turgut, Mamta Garg, Gurdeep Parmar, Brad Augustson, Nelson Castro, Edvan de Queiroz Crusoé, Tomáš Pika, Sosana Delimpasi, Kenichi Ishizawa, Anup George, Т. С. Константинова, Javier de la Rubia, Kim Sung-Hyun, Ângelo Maiolino, Tony Reiman, Richard LeBlanc, Shigeki Ito, Junji Tanaka, А. С. Лучинин, I. V. Kryuchkova, Joaquín Martínez‐López, Jesse Shustik, Lionel Karlin, Anargyros Symeonidis, Miklós Egyed, Mario Petrini, Michèle Cavo, Michihiro Uchiyama, Hilary Blacklock, Mutlu Arat, James E. Griffin, Hannah Hunter, Tonda Buck, Αchilles Anagnostopoulos, Κωνσταντίνος Κωνσταντόπουλος, Tamás Masszi, Sara Bringhen, Barbara Gamberi, Yawara Kawano, Kim Jin Seok, Hakan Özdoğu, Fahir Özkalemkaş - The Lancet 2021 cited by 380

  8. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 363

  9. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey Shang-Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Kathryn P. Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C. Anderson, Simon J. Harrison, Wojciech Janowski, Ian Kerridge, Andrew Spencer, Michel Delforge, Karel Fostier, Philip Vlummens, Ka Lung Wu, Richard LeBlanc, Michel Pavic, Michaël Sébag, Roman Hájek, Vladimír Maisnar, Luděk Pour, Henrik Gregersen, Lotfi Benbouker, Denis Caillot, Martine Escoffre‐Barbe, Thierry Façon, Laurent Frenzel, Cyrille Hulin, Lionel Karlin, Brigitte Kolb, Brigitte Pegourié, Aurore Perrot, Mourad Tiab, Laure Vincent, Dietger Niederwieser, Αchilles Anagnostopoulos, Sosana Delimpasi, Marie‐Christine Kyrtsonis, Anargyros Symeonidis, Árpád Illés, Gábor Mikala, Zsolt Nagy, Sara Bringen, Paolo Corradini, Fabio Ciceri, Roberto M. Lemoli, Anna Marina Liberati, Chiara Nozzoli, Renato Zambello, Shinsuke Iida, Takashi Ikeda, Satoshi Iyama, Morio Matsumoto, Chihiro Shimazaki, Kazutaka Sunami, Kenshi Suzuki, Michihiro Uchiyama, Youngil Koh, Kihyun Kım, Jae Hoon Lee, Chang‐Ki Min, Hillary Blacklock, Hugh J. B. Goodman, Annette Neylon, David Simpson, Sebastian Grosicki, Artur Jurczyszyn and 30 more - The Lancet 2019 cited by 636

  10. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Mario Boccadoro, Michèle Cavo, Javier de la Rubia Comos, Sosana Delimpasi, Meletios Α. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Façon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hájek, Güner Hayri Özsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Eirini Katodritou, Stefan Knop, Marie‐Christine Kyrtsonis, Juan José Lahuerta, Xavier Leleu, Carmen Martínez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique C. Minnema, Philippe Moreau, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlıvan, Luděk Pour, Henk Roerdink, Laura Rosinol Dacsh, Hans Salwender, Pieter Sonneveld, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tülin Tuğlular, Ali Ünal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman - The Lancet Oncology 2021 cited by 327

  11. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2023 cited by 124

  12. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2020 cited by 275

  13. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tom Willis, Malek Faham, Kenneth C. Anderson, Jean‐Luc Harousseau, Xavier Leleu, Thierry Façon, Philippe Moreau, Michel Attal, Hervé Avet‐Loiseau, Nikhil C. Munshi - Blood 2018 cited by 420

  14. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Eirini Katodritou, Hanna Oliynyk, Sybiryna Korenkova, Jeevan Kumar, Sundar Jagannath, Philippe Moreau, Moshe Levy, Darrell White, Moshe E. Gatt, Thierry Façon, María‐Victoria Mateos, Michèle Cavo, Donna Reece, Larry D. Anderson, Jean-Richard Saint-Martin, Jacqueline Jeha, Anita Joshi, Yi Chai, Lingling Li, Vishnuvardhan Peddagali, Melina Arazy, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Meletios Α. Dimopoulos, Paul G. Richardson, Sosana Delimpasi - The Lancet 2020 cited by 324

  15. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 cited by 564

  16. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 cited by 268

  17. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2023 cited by 95

  18. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Surbhi Sidana, Giampaolo Merlini, Tom Martin, Yi Lin, Ajai Chari, Rakesh Popat, Jonathan L. Kaufman - The Lancet Oncology 2024 cited by 119

  19. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 110

  20. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 179

  21. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

    Authors: , , , , , , , , , , - The Lancet 2020 cited by 422

  22. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cyrille Touzeau, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Fritz Offner, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Maria Krevvata, Ke Zhang, Carla de Boer, Sanjay Vara, Tobias Kampfenkel, Véronique Vanquickelberghe, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld - The Lancet Oncology 2021 cited by 175

  23. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 535

  24. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

    Authors: , , , , , , , , , - Blood Advances 2023 cited by 94